Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Coronavirus (COVID-19)| January 04, 2021

COVID Vaccines May Make the Future Brighter in 2021, if They Ever Arrive

The U.S. Government promised to have 20 million people vaccinated by Jan. 1, 2021 with just the Pfizer Vaccine. Even with two vaccines now approved, U.S. vaccinations for COVID stand at less than 4.5 million on Jan. 4, 2020. Getty Images The Pfizer and Moderna COVID vaccines were hailed as a major accomplishment in modern science and as the beginning of the end for COVID. This very well may be true, but it absolutely will not happen as fast as the government has led us to believe. #COVID19 #COVID #SARScov2

The U.S. Government promised to have 20 million healthcare workers and nursing home residents vaccinated by Jan. 1, 2021 with just the Pfizer vaccine. Even with two vaccines now approved, U.S. vaccinations for COVID stand at less than 4.5 million on Jan. 4, 2020. Getty Images

There was much fanfare over the U.S. Food and Drug Administration (FDA) emergency use authorizations (EUAs) in December for the Pfizer and Moderna COVID-19 (SARS-CoV-2) vaccines. However, the vaccination program to date has fallen very far short the promises made by the government when the first vaccine was approved, with less than one quarter of the promised vaccine being delivered.

The vaccines were hailed as a major accomplishment in modern science and as the beginning of the end for COVID. This very well may be true, but it absolutely will not happen as fast as the government has led us to believe. 

The Pfizer vaccine was approved Dec. 14, and the Centers for Disease Control (CDC) and federal officials said the plan was to get the first doses to 20 million Americans by Jan. 1, 2021. The second Moderna vaccine, approved Dec. 18, was supposed to add millions of additional doses by the end of 2020 as well. As of today, Jan. 4, only about 4.5 million have actually been vaccinated, far below what was promised.

And this report comes as Pfizer reports it still has millions of doses awaiting shipment in its warehouse that the federal government has not yet picked up. The drug maker says delays in getting the shipments out to hospitals is due to the federal government's logistical issues, not an issue with production and supply. If this is the case, the federal government should have done more to prepare for the vaccine with procuring adequate transportation and deep-freezer capacity. It appears the government was caught off guard and unprepared, but knew for months what was required for the handling of these fragile messenger RNA (mRNA) vaccines that need to be stored at minus 80 degrees below zero.

However, this preparedness has been handicapped by President Trump's poor leadership, because he believes the Democrats are more of a threat to the nation than the virus. The federal leadership for preparedness and response to contain and confront the virus has been severely lacking, uncoordinated, not based on science and made into a political debate rather than a scientific discussion. Doctors, scientific leaders and agencies like the CDC who could take the lead have largely been muzzled due to Trump's poor leadership.

After tuning out the news for the week of New Years, I found today, Jan. 4,  the news is filled with stories on why the roll out has been so slow. Most sources place blame on federal officials for not getting out the doses as fast as they originally promised weeks ago. States are saying they are dispensing all the doses they have received and are waiting for additional, promised shipments that have been delayed from the federal level. 

Most states and hospitals are reporting much smaller shipments of doses than originally anticipated. Since the supply appears to be limited and quantities being shipped are not guaranteed, many healthcare systems are holding back 50 percent of the doses they have already received. This is to ensure they have enough supply to deliver the second vaccination 18-21 days after the first injection for all those who already received their first dose. 

At this point, only healthcare workers, nursing home workers and nursing home residents are eligible in Phase 1a of the CDC plan to roll out the vaccines. The CDC estimated there are 21 million U.S. healthcare personnel and 3 million nursing home residents that are first in line to receive the vaccines. At the current rate of vaccination, it will take until late March to vaccinate everyone in the Phase 1a group before moving on to other essential workers. It is estimated at least 40-60 million others fall into the Phase 1b and 1c groups that are next in line before the general population will be able to receive the vaccine. At the current rate of vaccination, the general public would not be able to get vaccinated until August or September. 

Read more on Who Qualifies for the COVID Vaccine Under CDC Guidelines

I am happy to report my wife, a pharmacist with Northwestern Medicine in the Chicago area, was able to get the vaccine as an early Christmas present Dec. 21. However, for average people like myself, I do not expect to be able to get the vaccine much before mid to late summer 2021, based on what I am seeing with the the current roll out. This means that "normal" life will not return until maybe mid-fall of 2021 at the earliest, unless the U.S. government steps up its game on vaccine distribution and the virus is depoliticized.

The vaccine also takes on a new urgency in some regions that are in the middle of a massive wave of COVID hospitalizations and are about to be overwhelmed. This includes at least one county in southern California reporting 0 to 1.5 percent open ICU bed capacity. 

Since early December, COVID deaths have averaged between 2,000-3,000 deaths per day. This is equal to losing as many people as we did on Sept. 11, 2001, every day for a month straight. The U.S. just crossed 350,000 dead from the pandemic, which for comparison, far outnumbers all the U.S. military casualties from all conflicts since WWII combined. 

In this sense, we are at war with the virus, and so far it is doing a much better job of killing Americans than the diligent efforts of all of our enemies combined from the past 75 years. Hopefully in 2021, this country begins to treat the fight against COVID more as a war effort and not as just an inconvenience to their lives, or shrug it off as a low-grade sickness that is not any worse than the flu. 

Wishing everyone a healthy new year.  

I am interested to hear how the vaccine roll out is going at your hospitals and I am collecting images of clinicians getting their vaccine. Feel free to e-mail me at [email protected]
 

Find more COVID-19 related content

Related Content

Cardiologists are taking a closer look at the possible long-term cardiovascular effects on COVID long-hauler patients who still show symptoms long after they should be recovered from the virus. Getty Images

Cardiologists are taking a closer look at the possible long-term cardiovascular effects on COVID long-hauler patients who still show symptoms long after they should be recovered from the virus. Getty Images

Feature | Coronavirus (COVID-19) | January 22, 2021 | Dave Fornell, Editor
With nearly a year of experience with the...
A recent Society for Cardiovascular Angiography and Interventions (SCAI) survey found nearly 40 percent of Americans still do not feel safe going to the doctor's office while coronavirus is still a risk. Survey respondents also said they are more afraid of catching the virus than they are of a heart attack or stroke, which may delay critical treatment. Getty Images

A recent Society for Cardiovascular Angiography and Interventions (SCAI) survey found nearly 40 percent of Americans still do not feel safe going to the doctor's office while coronavirus is still a risk. Survey respondents also said they are more afraid of catching the virus than they are of a heart attack or stroke, which may delay critical treatment. Getty Images

News | Coronavirus (COVID-19) | January 18, 2021
January 18, 2021 — According to a new national survey released Jan.
Myocarditis among recovering COVID-19 athletes less common than previously reported

Myocarditis among recovering COVID-19 athletes appears to be less common than previously reported. Getty Images

News | Coronavirus (COVID-19) | January 12, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association (AHA) ...
The AHA and American Medical Society for Sports Medicine are collaborating to evaluate impact of COVID on the hearts of athletes, improve detection and inform safe return to play. #COVID19

The AHA and American Medical Society for Sports Medicine are collaborating to evaluate impact of COVID on the hearts of athletes, improve detection and inform safe return to play. Getty Images

News | Coronavirus (COVID-19) | January 12, 2021
January 12, 2021 — The American Heart Association (AHA) and the Ameri...
While the FDA said the risk that SARS-CoV-2 virus mutations will only have a minor impact on testing accuracy is low, the agency singled out three tests are they had a higher concern. FDA warns PCR tests may be innaccurate with new UK virus varient.

While the FDA said the risk that SARS-CoV-2 virus mutations will only have a minor impact on testing accuracy is low, the agency singled out three tests are they had a higher concern.

Feature | Coronavirus (COVID-19) | January 08, 2021 | Dave Fornell, Editor
January 8, 2021 — The U.S.
Who Can Get the COVID-19 Vaccine? Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, a nurse at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, OTR/L, director of rehabilitation at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

News | Coronavirus (COVID-19) | January 04, 2021 | Dave Fornell, Editor
The Centers for Disease Control and Prevention (CDC) Dec.
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulan
The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older. #COVID19 #SARSCoV2 #Vaccine

The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older.

News | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — The U.S.
Coronavirus SARS-CoV-2 colorized scanning electron micrograph of a cell (pink) heavily infected with SARS-CoV-2 virus particles (teal and purple), isolated from a patient sample. Image courtesy of NIAID. MIS-C Multisystem inflammatory syndrome in children. #COVID19

Coronavirus SARS-CoV-2 colorized scanning electron micrograph of a cell (pink) heavily infected with SARS-CoV-2 virus particles (teal and purple), isolated from a patient sample. Image courtesy of NIAID.

News | Coronavirus (COVID-19) | December 22, 2020
December 22, 2020 — An observational study has launched to evaluate the short- and long-term health outcomes of SARS-
The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec, 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance.  #COVID #COVID19 #SARSCoV2 #vaccine #COVIDVaccine

The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec. 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance. 

Feature | Coronavirus (COVID-19) | December 14, 2020 | Dave Fornell, Editor
December 14, 2020 — The U.S.